Physician profile
Charles E Thomas
NPI 1922018209
$1,488.58
in general payments reported to CMS, 2019-2025
14 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $244 · 2023: $352 · 2024: $277 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $432.10 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $354.97 | 2021-2024 | Qelbree, Qelbree |
| Sobi, INC | $168.95 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $97.18 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $80.39 | 2021-2024 | |
| Sanofi Pasteur INC. | $78.90 | 2021-2025 | |
| Glaxosmithkline, LLC. | $78.30 | 2021-2023 | Bexsero |
| Adlon Therapeutics L.P. | $59.84 | 2021 | |
| Tris Pharma INC | $41.32 | 2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $35.78 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $18.63 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.71 | 2021 | |
| Neos Therapeutics, LP | $13.39 | 2021 | |
| Vertical Pharmaceuticals, LLC | $13.12 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.